43 results about "Heart right" patented technology

A catheter includes a catheter body, a pump assembly and a cannula. The pump assembly can be disposed at a distal end of the catheter body and has a distal portion. The cannula can be coupled to the distal end portion of the pump assembly and can include a proximal cannula portion and a distal cannula portion. The distal cannula portion has an approximately helical shape which can allow the cannula to be inserted into a patient's right heart and pump blood therethrough. In certain implementations, the distal tip of the helical shape has a slight bias relative to the main helix to further facilitate delivery of the device. In certain applications this bias is toward the central axis of the helix.

The invention provides an automatic counting method and system for ultrasonic microbubbles in right heart acoustic radiography. The method comprises the following steps: acquiring a cardiac radiography image of a patient through high-resolution ultrasonic equipment; extracting a region of interest of the cardiac angiography image based on the cardiac vascular structure, and performing image registration operation on the cardiac angiography image by taking the region of interest as a reference point to obtain a registered image; carrying out pixel-by-pixel addition on two frames of pulse images with opposite phases in the registered image to obtain an enhanced image; determining the high-echo bright spots in the enhanced image as suspected microbubbles, and performing denoising processing according to the feature similarity to obtain real microbubbles; judging pathological conditions according to whether real microbubbles exist in the left atrium or not; if the real microbubbles exist in the left atrium, grading the abnormal blood flow according to the change data of the microbubbles in the left atrium and the right atrium. According to the method, through high-precision image registration, multi-modal feature analysis and dynamic parameter fusion technologies, the microbubble detection accuracy is improved, and quantitative grading of pathological conditions is achieved.

The invention discloses a blood leakage rate measuring device and method and a clinical actual blood flow obtaining method. The blood leakage rate measuring device comprises a right heart simulator filled with liquid and a pulmonary artery simulator, a second pressure sensor and a first pressure sensor are installed at the bottom in the right heart simulator and the pulmonary artery simulator, the right heart simulator is communicated with the pulmonary artery simulator through a first pipeline and a second pipeline, and an auxiliary pump is installed on the first pipeline. The right heart auxiliary catheter penetrates through the right heart simulator, the valve assembly is arranged in liquid in the right heart simulator, the end cap is arranged in liquid in the pulmonary artery simulator, a second flow sensor is installed on the outer wall of the short tube part between the right heart simulator and the pulmonary artery simulator, and a first flow sensor is installed on the outer wall of the long tube part close to the extracorporeal membrane type cavity. According to the clinical actual blood flow obtaining method, the actual blood flow of the right heart auxiliary catheter can be accurately obtained through the obtained blood leakage rate.

The invention belongs to the technical field of medical ultrasonic diagnosis auxiliary equipment, and discloses an electric right heart acoustic radiography foaming device which comprises a device body, the device body comprises a base, a mounting plate is fixedly arranged on the rear side of the base, a driving assembly is arranged on the front side of the mounting plate, and the driving assembly comprises fixing frames fixed to the upper side and the right side of the mounting plate; a stepping motor is fixedly arranged at the top of the fixing frame, a ball screw is fixedly arranged at the tail end of a main shaft of the stepping motor, a sliding block is spirally arranged on the outer side of the ball screw in a sleeving mode, and a connecting rod is fixedly arranged at the bottom of the sliding block, so that accurate controllability of power transmission and visual adjustment of parameters in the contrast agent injection process are achieved; specifically, key parameters such as injection speed and dosage can be accurately set through the operation panel, a traditional manual injection mode is replaced, and the stability of the foaming effect of the contrast agent is guaranteed.

The invention relates to the technical field of medical instruments, in particular to an intelligent catheter implanted right heart blood flow management system, a blood pumping impeller comprises a hub structure and a blade assembly fixed around the hub structure, and the near end of a hub is an annular concave curved surface used for guiding blood flow; the blade assembly comprises two symmetrical continuous blades with the same thickness, and the placement angles of the blades are gradually increased from the near end to the far end. The design structure that the segmented hub and the continuous blades are combined is adopted, all segments of the hub structure have different geometrical characteristics, the molded line of each continuous blade is formed by combining an arc and a straight line, and the design of a gradually-increased setting angle and a large wrap angle is matched with the design of a parabola at the far end of the hub, so that the shear stress and the flow dead zone are reduced, and the service life of the impeller is prolonged. Therefore, the risks of hemolysis and thrombus are reduced, the blood flow path is optimized under the miniaturized condition, the catheter implantation type miniature axial flow blood pump is more suitable for the blood flow flowing characteristic in the catheter implantation type miniature axial flow blood pump, and smooth transition from radial inflow to axial outflow of blood can be achieved.

The invention discloses a pulmonary arterial hypertension recognition device and method based on multiple paths of electrocardio heart sound signals, and relates to the technical field of biomedicine, and the method comprises the steps: limiting an aortic valve closing candidate peak and a drop point of a pulmonary valve closing candidate peak in a time interval between a main peak anchor point time boundary of a double-anchoring split fragment set and an electrocardio fragment key turning point; adjacent beat backtracking replacement and multi-channel consistent voting retention are performed on candidate peaks of cross-beat hopping, and a physiological consistent split fragment set is generated; and according to the physiological consistency split fragment set, converging split sequences of multiple paths of heart sounds, and carrying out beat-level splicing and in-window consistency closing on the split sequences and right heart load related form entries of multiple paths of electrocardio, so as to generate a pulmonary arterial hypertension recognition and diagnosis set. According to the method, high-precision synchronization of multiple paths of electrocardiogram and heart sound signals is realized, equipment difference and noise interference are eliminated, the reliability of feature extraction is guaranteed, and the pulmonary arterial hypertension recognition stability is improved.

The invention discloses application of scopalactone in treatment of pulmonary arterial hypertension, and relates to the technical field of medicinal chemistry. The scoparone is applied to preparation of the medicine for treating pulmonary arterial hypertension. The medicine comprises scopalactone, a pharmaceutically acceptable carrier, a diluent and an excipient, the medicine further comprises other medicines for treating the pulmonary arterial hypertension, and the other medicines for treating the pulmonary arterial hypertension are selected from a prostacyclin medicine, an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. The scopalactone is applied to preparation of the medicine for treating pulmonary arterial hypertension, right heart insufficiency caused by hypoxia can be remarkably reversed, and the right heart function is effectively improved by reducing the transverse diameter of the right ventricle and the transverse diameter of the right atrium and improving the indexes such as tricuspid valve ring plane contraction displacement; the average pulmonary arterial pressure and right ventricular systolic pressure can be obviously reduced, and hemodynamic parameters are improved; the area and thickness of a blood vessel wall can be remarkably reduced, the blood vessel structure is improved, and pulmonary arteriole reconstruction is relieved.

This invention discloses a method for controlling left and right ventricular compression before extracorporeal circulation. First, in an in vitro environment, peristaltic pumps are installed at the left and right ventricular inlets of the extracorporeal circulation device. Then, an inlet pump is connected to the inlet of the peristaltic pumps, and an outlet pump is connected to the outlet of the peristaltic pumps. Finally, a first pressure measuring structure and a second pressure measuring structure are respectively installed on the side of the inlet and outlet pumps away from the peristaltic pumps, and the pressure of both the inlet and outlet pumps is adjusted to -180 mmHg. The negative pressure of the inlet pump is adjusted by the first pressure measuring structure, and the negative pressure of the outlet pump is adjusted by the second pressure measuring structure, thereby quantifying the adjustment method. This visualizes the process of controlling left and right ventricular compression before extracorporeal circulation, converting the adjustment results into specific negative pressure values ​​for the inlet and outlet pumps. This makes the reference values ​​for adjusting left and right ventricular compression numerically and standardized, avoiding adjustment discrepancies, eliminating reliance on experience and intuition, and providing a quick and highly accurate adjustment method.

The invention relates to the technical field of medical equipment, and provides a right heart suction tube assembly. The right heart suction tube assembly comprises negative pressure equipment, a tube body, a diaphragm, a suction head, a first baffle and a second baffle. The tube body comprises a tube head end and a tube tail end; the interior of the tube body is divided into a first tube cavity and a second tube cavity by the diaphragm; the suction head is arranged at the tube head end; the first baffle is movably arranged in the first tube cavity, the first baffle comprises a first position and a second position, and when the right heart suction tube assembly works normally, the first baffle is located at the first position, and when the first baffle is located at the second position, the first baffle blocks the first tube cavity; the second baffle is movably arranged in the second tube cavity, the second baffle comprises a third position and a fourth position, and when the right heart suction tube assembly works normally, the second baffle is located at the third position, and when the second baffle is located at the fourth position, the second baffle blocks the second tube cavity. According to the right heart suction tube assembly, the phenomenon that the right heart suction tube assembly is completely blocked in an operation can be avoided.

A heart failure management system for a patient includes a plurality of sensors including at least one implantable pressure sensor positioned within the heart to capture synchronized left and right heart pressure waveforms, transmitted via one or more transmitters to a receiver. Control circuitry receives these waveforms and processes them using a machine learning medication dosage management model, trained on historical left and right heart pressure logs, volume status metrics (e.g., weight, fluid intake, symptoms), and / or ground truth dosage logs for certain heart failure treatment medications, such as a blood pressure reducing medication (e.g., ARNI) and an intravascular volume reducing medication (e.g., Lasix). The model can generate real-time dosage recommendations, systemic blood pressure, and volume load predictions in real-time, enabling precise, data-driven treatment adjustments aligned with clinical guidelines, supporting timely clinical decisions or automated medication dispensing to optimize patient outcomes and reduce hospitalization risks.

According to one aspect of the disclosure, a method of advancing a delivery catheter to a heart of a patient includes advancing a guidewire through the vasculature of the patient until the guidewire reaches a target treatment site in or adjacent to the heart. A dilator may be positioned within the delivery catheter so that a distal tip of the dilator extends beyond a distal end of the delivery catheter. The dilator may be advanced through the vasculature of the patient directly over the guidewire while simultaneously advancing the delivery catheter through the vasculature until the distal tip of the dilator reaches the target treatment site. While maintaining the distal tip of the dilator substantially stationary relative to the target treatment site, the delivery catheter may be advanced over the dilator until the distal end of the delivery catheter is positioned at the target treatment site.

The invention discloses an endothelium targeted controlled-release antithrombotic drug intelligent monitoring biodegradable heart occluder, and relates to the field of medical instruments, the heart occluder comprises an occluder main body and a sheathing canal for regulating and controlling the occluder main body, the occluder main body is composed of a double-disc-shaped biological skeleton, a fixed deformation body and a biological flow blocking film, the double-disc-shaped biological skeleton is composed of two attaching discs which are mutually symmetrical to form a left center disc face and a right center disc face, a support outer disc is arranged on the side surfaces of the attaching discs in a surrounding mode, and a double-layer antithrombotic drug controlled release layer is arranged on the surface of the support outer disc; the two attaching plates are tightly connected with the fixed deformation body, an ultrasonic blood flow sensor is arranged in the fixed deformation body, an impedance sensor is arranged at the position, located on one side of the ultrasonic blood flow sensor, in the fixed deformation body, and the biological flow blocking films are arranged on the surfaces of the opposite sides of the two attaching plates respectively. The plugging device is periodically degraded in the body of a patient to reduce complications caused by foreign matter retention, and aiming at thrombus formation on the surface of the plugging device, middle and low doses of antithrombotic drugs are locally controlled, so that whole-body adverse reactions caused by long-term oral administration of the antithrombotic drugs after the plugging operation are reduced. Thrombus risk and occluder endothelialization process are dynamically monitored to assist in repair and regeneration of heart tissue.

The invention provides a right heart failure detection method and device.The method comprises the steps that a first pumping flow curve is obtained, and the first pumping flow curve is a pumping flow curve within a target period when a ventricular assist device operates at a target rotating speed; determining at least one target parameter according to the first pumping flow curve; and if the at least one target parameter meets the preset condition, determining that the right heart failure exists. The target parameters capable of measuring the state of the right heart are obtained from the pumping flow curve of the ventricular assist device implanted into the left heart in real time, whether the current ventricular assist device causes the right heart failure or not is determined through comparison, and real-time detection of the right heart failure is achieved.

The present invention discloses a device and method for accurately adjusting the compression tightness of the left and right hearts during extracorporeal circulation, and relates to the technical field of medical devices. The device for accurately adjusting the compression tightness of the left and right hearts during extracorporeal circulation comprises a first connector, a sterile saline bag, a first pipeline, a first flow stopper, a second connector, and a second pipeline; the first connector is suitable for being installed on the liquid inlet pipeline of a roller pump; the liquid outlet end of the sterile saline bag is connected to the first connector through the first pipeline; the first flow stopper is suitable for being arranged on the liquid inlet pipeline of the roller pump and clamping the blood inlet end of the first connector; the second connector is suitable for being installed on the liquid outlet pipeline of the roller pump, and the second connector is detachably connected to the pulmonary membrane through the second pipeline; the second flow stopper is suitable for being arranged on the liquid outlet pipeline of the roller pump and clamping the bleeding end of the second connector. The present invention provides a device and method for accurately adjusting the compression tightness of the left and right hearts during extracorporeal circulation, which greatly improves the accuracy and convenience of adjusting the compression tightness of the left and right hearts during extracorporeal circulation.

The application discloses a use of taibai araloside in treating hypoxic pulmonary arterial hypertension. In the use of hypoxia to induce pulmonary arterial hypertension, it is found that the taibai araloside can reduce right ventricular pressure and right heart hypertrophy index, and inhibit pulmonary arterial remodeling; the taibai araloside reduces the expression and activity of ACE in the lung in a concentration-dependent manner, and corrects the disorder of the RAS system in the lung caused by hypoxic pulmonary arterial hypertension. Moreover, a monomer component of the taibai araloside, anemarrhena asphodeloides glycoside and chizhenshan saponin IVa, has a stable combination with ACE. The results show that the taibai araloside has the potential to be developed into a drug for preventing and treating hypoxic pulmonary arterial hypertension in the clinic, and also provides a prevention and treatment strategy for interstitial lung disease, chronic obstructive pulmonary disease, sleep apnea syndrome, chronic high altitude disease and neonatal respiratory disease.

The application discloses a pulmonary arterial hypertension recognition device and method based on multiple ECG and PCG signals, and relates to the technical field of biomedicine. The device comprises the following steps: limiting the landing points of the aortic valve closing candidate peak and the pulmonary valve closing candidate peak in the main peak anchor point time boundary and the ECG segment key turning point time interval of the double-anchored split segment set, performing adjacent beat backtracking replacement and multi-channel consistent voting reservation on the candidate peak of the cross-beat jump, and generating a physiological consistency split segment set; according to the physiological consistency split segment set, gathering the split sequence of the multiple PCGs, and performing beat-level splicing and window-in-consistency closure on the right heart load related morphological items of the multiple ECGs, and generating a pulmonary arterial hypertension recognition diagnosis set. The application realizes high-precision synchronization of multiple ECG and PCG signals, eliminates device differences and noise interference, guarantees the reliability of feature extraction, and improves the stability of pulmonary arterial hypertension recognition.

The present invention concerns the field of diagnostics. In particular. It relates to a method for assessing a heart valve disease or disorder comprising the steps of a) determining the amount of a BMPlO-type peptide in a sample of said subject, and b) comparing the amount determined in step a) to a reference, whereby the heart valve disease or disorder is assessed. Further, the invention concerns computer-implemented methods of the aforementioned methods as well as devices and kits for carrying out said methods. Yet, the present invention contemplates the general use of a BMPlO-type peptide in a sample of a subject or a detection agent for a BMPlO-type peptide to be applied in said sample for assessing a heart valve disease or disorder.

1. The name of the design product: silicone mold (heart double-pasted candle). 2. The use of the design product: silicone mold for making heart double-pasted candle by dripping glue. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: assembly 1 perspective view 1. 5. Other circumstances that need to be explained: in the design, component 1 is a left heart candle, and component 2 is a right heart candle.

This invention relates to a simulator for transcatheter interventional treatment of right ventricular valves, comprising a model mounting housing with multiple simulated liquid inlet channels and multiple simulated liquid outlet channels disposed in the left and right side walls of the housing; the multiple liquid inlet channels are connected to a shunt device via pipes, the shunt device is connected to a heating device via pipes, the heating device is connected to a simulated liquid storage device via pipes, the simulated liquid storage device is connected to a manifold via pipes, the manifold is connected to the simulated liquid outlet channels via pipes, and a liquid pump is also disposed between the simulated liquid storage device and the heating device; the simulator for transcatheter interventional treatment of right ventricular valves can simulate the flow of blood in a pulsating conduit model, thereby more realistically simulating the process of transcatheter interventional treatment of right ventricular valves, allowing doctors to simulate surgery in a model that is closer to a real environment before performing actual surgery, thereby improving the success rate of the surgery.

The invention discloses a system and method for diagnosing pulmonary tuberculosis-pulmonary arterial hypertension through artificial intelligence chest CT imaging, and the system comprises a data acquisition module which is used for collecting a chest CT image of a patient in the supine position full inspiration period, and exporting the CT image in a DICOM format; the data processing module is used for carrying out full-lung automatic segmentation and lung lobe segmentation VTDLT calculation by using an AI algorithm through AI image analysis software; the quantitative analysis module is used for outputting the damage volume and the number and distribution of the affected lung lobes; the risk prediction module is used for combining the VTDLT with clinical parameters to construct a PH risk prediction model; according to the application, the pulmonary arterial hypertension is screened by combining CT imaging with an artificial intelligence algorithm, an original mode of screening through right heart catheter examination is not changed, a noninvasive, early-stage and accurate PH screening tool is provided for TDL patients, the use requirements of RHC are reduced, and the pain and medical burden of the patients are relieved.

The invention, which belongs to the technical field of the medical equipment, discloses a lung transplantation post-operative cardiopulmonary capacity collaborative evaluation and adjustment system comprising a multi-parameter acquisition module, a cardiopulmonary interaction modeling module, a capacity strain test module, a haemodynamics target setting module, a treatment response prediction module and an adjustment execution module. The system quantitatively analyzes the complex relationship among the right heart function, the pulmonary vascular resistance and the pulmonary compliance through a cardiopulmonary interaction modeling engine, evaluates the tolerance of a patient to the capacity change through a capacity strain test, and formulates an individualized hemodynamic target according to a specific cardiopulmonary interaction mode of the patient. Potential influences of different intervention measures are simulated, treatment parameters are automatically adjusted, the hemodynamic stability and the oxygenation function of a lung transplantation patient are remarkably improved, and the occurrence rate of complications is reduced.

The utility model discloses a right heart acoustic contrast auxiliary device with reinforcing component, include: support seat, the upper portion of support seat is provided with syringe, the upper portion of support seat is provided with the reinforcing mechanism for the syringe spacing, the outside of support seat is provided with the push mechanism for reducing medical staff hand labor intensity. The processing mechanism including clamping block, toothed block, mounting block, fixed block and threaded rod is arranged on the upper portion of support seat. The right heart acoustic contrast auxiliary device with reinforcing component, through setting up reinforcing mechanism, can firmly limit and fix syringe, can effectively avoid the separation of syringe and medical three -way connection in the pulling process, at the same time setting up push mechanism, can effectively reduce medical staff hand labor intensity, secondly setting up anti -movement mechanism, also firmly limit medical three -way, can make syringe can to medical three -way stable contrast medium input.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating pulmonary arterial hypertension, and relates to the technical field of traditional Chinese medicines. The invention provides a traditional Chinese medicine composition Jinshui ten-component decoction in a medicine for treating pulmonary arterial hypertension. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-50 parts of raw astragalus membranaceus, 10-30 parts of codonopsis pilosula, 10-25 parts of salvia miltiorrhiza, 8-20 parts of safflower carthamus, 10-25 parts of herba lycopi, 6-15 parts of winged euonymus twig, 10-20 parts of semen lepidii, 10-25 parts of poria cocos, 3-10 parts of white mulberry root-bark and 10-25 parts of semen plantaginis. The traditional Chinese medicine compound is based on the treatment principle of tonifying qi, activating blood and inducing diuresis to alleviate edema of traditional Chinese medicine, realizes multi-target regulation and control, effectively reduces pulmonary arterial pressure, improves right heart function and reverses pulmonary vascular remodeling through synergistic compatibility of multiple traditional Chinese medicines, has the advantages of high safety, low price and suitability for long-term administration, and provides a new effective choice for treatment of pulmonary arterial hypertension.

The utility model belongs to the technical field of pulmonary vessel guiding catheters, and particularly relates to a pulmonary vessel guiding catheter which can be used for right heart function examination. The technology comprises a guiding catheter, and a floating catheter is arranged in the guiding catheter in a penetrating mode. According to the technical scheme, the functions of an existing right heart floating catheter and an existing pulmonary vessel guiding catheter are organically combined, and the function effects of the original right heart floating catheter and the original pulmonary vessel guiding catheter are achieved through one set of technical scheme. Specifically, a guiding catheter in the prior art is adopted, and physical characteristics such as proper flexibility and strength are utilized to adapt to various bends and steers in a blood vessel; a floating catheter in the prior art is adopted to realize pulmonary vessel intervention operation; the floating catheter is arranged in the guiding catheter, so that the guiding catheter can be used for right heart function examination and pulmonary vessel intervention operation, and clinical diversified requirements are met.

This specification discloses a control system for an artificial heart. This control system comprises a rotary first pump that replaces or assists the function of the left heart of a living organism, and a rotary second pump that replaces or assists the function of the right heart of a living organism.

The invention discloses a heart beat and blood circulation dynamic teaching model, and belongs to the technical field of biological teaching aids, and the model comprises a left heart and right heart independent elastic sealed cavity type heart simulation unit which is used for simulating the contraction and relaxation of the heart, is made of a flexible pipeline, is provided with a one-way control part, is used for limiting the one-way flow of blood, and has one end connected with the heart; one end of the blood vessel simulation unit is connected with a viscera, the viscera simulation unit is arranged according to the coronal plane of a human body, a closed channel is filled with the simulated blood medium containing two colors, the circulation driving unit is connected with a pipeline in series to drive blood circulation, and the control unit is electrically connected with the heart, the driving unit and the sound box. Through a heart simulation unit divided into a left heart and a right heart, heart actions are accurately simulated, and a heart beat cycle is presented; arteriovenous blood is clearly distinguished through two color media, and the transformation process is displayed.

The invention discloses a device for detecting and evaluating a right heart function after a heart transplantation operation. Relates to the technical field of medical instruments. The supporting assembly is arranged on the movable base in a rotatable mode; the cardiac ultrasound equipment is arranged on the supporting assembly; and the blood pressure and hemodynamics detection equipment is also arranged on the supporting assembly, and the blood pressure and hemodynamics detection equipment is arranged opposite to the cardiac ultrasound equipment. According to the detection device, ultrasonic detection can be conducted on the right heart function after the heart transplantation operation, meanwhile, pulmonary artery pressure and hemodynamic detection can be conducted, whether the structure and the function of the heart are abnormal or not is known by observing the right heart state after the transplantation operation, the heart function is closely detected after the operation, and the prognosis of a patient is remarkably improved.

The invention discloses a treprostinil microcrystal / temperature-sensitive gel system, which is prepared by the following steps: preparing treprostinil and a stabilizer into treprostinil microcrystals, and combining the treprostinil microcrystals with temperature-sensitive gel to obtain the treprostinil microcrystal / temperature-sensitive gel system, the treprostinil microcrystal is prepared from treprostinil and a stabilizer through a film hydration-ultrasonic method. The temperature-sensitive gel is a blank gel solution prepared from methylcellulose, sodium chloride and an additive; the additive is selected from one of polyethylene glycol 4000, polyvinylpyrrolidone K30, hyaluronic acid and bovine serum albumin. The treprostinil microcrystal / temperature-sensitive gel system can slow down burst release of drug microcrystals, prolong drug action time and improve patient compliance and safety. The treprostinil microcrystal-temperature-sensitive gel system can maintain the effective treatment concentration for 3 days after being injected once, and the treatment effect is achieved by reducing the average pulmonary arterial pressure and improving pulmonary vascular remodeling and right heart remodeling.